Validation, kinetic modeling, and test-retest reproducibility of [ 18 F]SynVesT-1 for PET imaging of synaptic vesicle glycoprotein 2A in mice
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Alterations in synaptic vesicle glycoprotein 2 A (SV2A) have been associated with several neuropsychiatric and neurodegenerative disorders. Therefore, SV2A positron emission tomography (PET) imaging may provide a unique tool to investigate synaptic density dynamics during disease progression and after therapeutic intervention. This study aims to extensively characterize the novel radioligand [ 18 F]SynVesT-1 for preclinical applications. In C57Bl/6J mice ( n = 39), we assessed the plasma profile of [ 18 F]SynVesT-1, validated the use of a noninvasive image-derived input function (IDIF) compared to an arterial input function (AIF), performed a blocking study with levetiracetam (50 and 200 mg/kg, i.p.) to verify the specificity towards SV2A, examined kinetic models for volume of distribution ( V T ) quantification, and explored test-retest reproducibility of [ 18 F]SynVesT-1 in the central nervous system (CNS). Plasma availability of [ 18 F]SynVesT-1 decreased rapidly (13.4 ± 1.5% at 30 min post-injection). V T based on AIF and IDIF showed excellent agreement (r 2 = 0.95, p < 0.0001) and could be reliably estimated with a 60-min acquisition. The blocking study resulted in a complete blockade with no suitable reference region. Test-retest analysis indicated good reproducibility (mean absolute variability <10%). In conclusion, [ 18 F]SynVesT-1 is selective for SV2A with optimal kinetics representing a candidate tool to quantify CNS synaptic density non-invasively.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1. Parent fraction and plasma analysis of [18F]SynVesT-1. (a) Population-based curve of intact radioligand in plasma following intraveneous injection and (b) Plasma to whole blood ratio of [18F]SynVesT-1. WB = whole blood. Data are mean ± SD. n = 3/5 per time point.](https://figures.cochat.ai/paper-figures/412c0d1af96c406c93c9051f4c14d2a3/validation-kinetic-modeling-and-test-retest-reproducibility-of-sup-18-sup-f-figure-1.jpg)
![Figure 2. Comparison of invasive and non-invasive input functions for [18F]SynVesT-1 quantification. (a) [18F]SynVesT-1 SUV time-activity curves in different brain regions during 120 min acquisition. (b) Comparison between average SUV time-activity curves for invasive (AIF) and noninvasive (IDIF) metabolite-corrected input functions during [18F]SynVesT-1 PET acquisition and (c) Pearson’s correlation between VT (IDIF) estimates based on invasive (AIF) and noninvasive (IDIF) metabolite-corrected input functions displayed excellent agreement (r2 = 0.95). Solid line represents the linear regression. n = 5. SUV = standardized uptake value.](https://figures.cochat.ai/paper-figures/6609998a46324c3881d524e3dc069535/validation-kinetic-modeling-and-test-retest-reproducibility-of-sup-18-sup-f-figure-2.jpg)
![Figure 3. Time stability and model comparison for [18F]SynVesT-1 quantification. VT (IDIF) estimates with different scan durations using 2TCM (a) and Logan plot (b) normalized to the values obtained with the 120 min acquisition. VT (IDIF) values based on 120 min and 60 min scan acquisition did not differ for both 2TCM (c) and Logan plot (d). Pearson’s correlation depicts the excellent agreement between VT (IDIF) based on 2TCM and Logan plot with both 120 min (e) and 60 min (f) scan acquisition. n = 10.](https://figures.cochat.ai/paper-figures/cf9b03b76eab4351b41bbc37929915a9/validation-kinetic-modeling-and-test-retest-reproducibility-of-sup-18-sup-f-figure-3.jpg)
![Figure 4. [18F]SynVesT-1 binds specifically to SV2A in the mouse brain. (a) MR template and mean [18F]SynVesT-1 parametric maps during baseline and following blockade with levetiracetam (LEV) (i.p., 30 min before radioligand injection) overlaid onto an MRI mouse brain template for anatomical localization. (b) Average striatal SUV time-activity curve during baseline and pretreatment with levetiracetam for a 60-min acquisition. (c) Striatal [18F]SynVesT-1 VT (IDIF) (Logan) during baseline and following blockade with LEV. ****p < 0.0001 and (d) Lassen plots for target occupancy at different doses of LEV show an estimated SV2A occupancy of 97% and 100%. Baseline: n = 12. Blocking: n = 6 per dose. SUV = standardized uptake value.](https://figures.cochat.ai/paper-figures/e94765c5ccf940f5a88bc61b9368599b/validation-kinetic-modeling-and-test-retest-reproducibility-of-sup-18-sup-f-figure-4.jpg)
![Figure 5. [18F]SynVesT-1 binding in the spinal cord. (a) Average spinal cord SUV time-activity curve during baseline and pretreatment with levetiracetam for a 60-min acquisition. (b) [18F]SynVesT-1 VT (IDIF) (Logan) during baseline and following blockade with LEV. ****p < 0.0001 and (c) Pearson’s correlation depicts the excellent agreement between striatal and spinal quantification. Baseline: n = 12. Blocking: n = 6 per dose. SUV = standardized uptake value.](https://figures.cochat.ai/paper-figures/54ef8c1d88ca419ebb62ab4ea476401c/validation-kinetic-modeling-and-test-retest-reproducibility-of-sup-18-sup-f-figure-5.jpg)
![Figure 6. Test-retest variability and reproducibility of [18F]SynVesT-1 VT (IDIF) based on 60-min acquisition. (a) Mean [18F]SynVesT-1 parametric maps during test and retest overlaid onto an MRI mouse brain template for anatomical localization. (b) Bland-Altman plot comparing test-retest VT (IDIF) estimates. The dotted lines represent the 95% limits of agreement and (c) Pearson’s correlation plot comparing test-retest VT (IDIF) estimates. The dashed line denotes the identity line. STR = striatum, THAL = thalamus, HC = hippocampus, CB = cerebellum, SC = spinal cord; n = 12.](https://figures.cochat.ai/paper-figures/185290341a8a4ca38873f9aee88da0e8/validation-kinetic-modeling-and-test-retest-reproducibility-of-sup-18-sup-f-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For the case of radiometabolites, a population-based metabolite correction could be a solution [157,158], but ideally this should be established for each tracer and validated in each animal model [152].”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [158]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Longitudinal SV2A PET is poised to answer these gaps, but validation demands harmonized kinetic modeling, test–retest data across centers, and standardized reference strategies from mouse to human cohorts [206,214,235,236].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [236]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This method has successfully been applied by Bertoglio et al. to estimate [ 11 C]UCB-J [157] and [ 18 F] SynVesT-1 [158] V T values in mice.”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [158]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Simplified Reference Tissue Model for PET Receptor Studies
Lammertsma, A. A., & Hume, S. P. (1996) · NeuroImage · doi:10.1006/nimg.1996.0066 · Cited by 2,021
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
Logan, J., Fowler, J. S., Volkow, N. D., Wolf, A. P., Dewey, S. L., Schlyer, D. J., MacGregor, R. R., Hitzemann, R., Bendriem, B., Gatley, S. J., et al. (1990) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1990.127 · Cited by 1,479 · cited 1×
“The fitting of the regional TACs was explored with the one-tissue compartmental model (1TCM), twotissue compartmental model (2TCM), and Logan plot method.(30) However, 1TCM failed to fit the regional TACs; therefore, 2TCM and Logan plot are presented.”
MethodMolecular machines governing exocytosis of synaptic vesicles
Jahn, R., & Fasshauer, D. (2012) · Nature · doi:10.1038/nature11320 · Cited by 970 · cited 1×
“Synaptic vesicle glycoprotein 2 (SV2) is a highly conserved protein family playing an essential role in neurotransmitter release from the presynaptic terminals following action potential stimulation.(1,2) Among the three SV2 (SV2A, SV2B, and SV2C) isoforms, SV2A, the binding target of the antiepileptic drug levetirace…”
BackgroundImaging synaptic density in the living human brain
Finnema, S. J., Nabulsi, N. B., Eid, T., Detyniecki, K., Lin, S.-F., Chen, M.-K., Dhaher, R., Matuskey, D., Baum, E., Holden, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf6667 · Cited by 575 · cited 1×
“Among the developed SV2A radioligands, [(11)C]UCB-J displayed optimal pharmacokinetics and quantification properties for measuring synaptic density in humans.(9,10) Additionally, it was demonstrated to offer an excellent clinical marker for the measurement of synaptic alterations in a variety of brain disorders, inclu…”
MethodLower synaptic density is associated with depression severity and network alterations
Holmes, S. E., Scheinost, D., Finnema, S. J., Naganawa, M., Davis, M. T., DellaGioia, N., Nabulsi, N., Matuskey, D., Angarita, G. A., Pietrzak, R. H., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09562-7 · Cited by 484
Differential expression of synaptic vesicle protein 2 (SV2) isoforms
Bajjalieh, S., Frantz, G., Weimann, J., McConnell, S., & Scheller, R. (1994) · The Journal of Neuroscience · doi:10.1523/jneurosci.14-09-05223.1994 · Cited by 440
Chen, M.-K., Mecca, A. P., Naganawa, M., Finnema, S. J., Toyonaga, T., Lin, S.-F., Najafzadeh, S., Ropchan, J., Lu, Y., McDonald, J. W., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1836 · Cited by 431
Waxholm Space: An image-based reference for coordinating mouse brain research
Johnson, G. A., Badea, A., Brandenburg, J., Cofer, G., Fubara, B., Liu, S., & Nissanov, J. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.06.067 · Cited by 261
Lassen, N. A., Bartenstein, P. A., Lammertsma, A. A., Prevett, M. C., Turton, D. R., Luthra, S. K., Osman, S., Bloomfield, P. M., Jones, T., Patsalos, P. N., et al. (1995) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1995.17 · Cited by 220
Research works printed but not linked: 2
- Cai Z, Neurosci Lett
- Finnema SJ, 2017, J Cereb Blood Flow Metab, 271678X17724947
Cited by
Synaptic changes in psychiatric and neurological disorders: State-of-the art of in vivo imaging
Howes, O., Marcinkowska, J., Turkheimer, F. E., & Carr, R. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01943-x · Cited by 34
Millevert, C., Vidas-Guscic, N., Vanherp, L., Jonckers, E., Verhoye, M., Staelens, S. G., Bertoglio, D., & Weckhuysen, S. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.1043-23.2023 · Cited by 20
Self-citationAsch, R. H., Abdallah, C. G., Carson, R. E., & Esterlis, I. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01913-3 · Cited by 13
Synaptic density in aging mice measured by [18F]SynVesT-1 PET
Xiong, M., Roshanbin, S., Sehlin, D., Hansen, H. D., Knudsen, G. M., Rokka, J., Eriksson, J., & Syvänen, S. (2023) · NeuroImage · doi:10.1016/j.neuroimage.2023.120230 · Cited by 13
Li, B., Chen, H., Zheng, Y., Xu, X., You, Z., Huang, Q., Huang, Y. H., Guan, Y., Zhao, J., Liu, J., et al. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06862-z · Cited by 15
“A blocking study using levetiracetam validated the specificity of SynVesT-1 for SV2A, with complete blockade indicating the selectivity of SynVesT-1 for SV2A and its potential as a non-invasive tool to quantify central nervous system synaptic density [38].”
Metadata
- Authors
- Bertoglio, D., Zajicek, F., Lombaerde, S. D., Miranda, A., Stroobants, S., Wang, Y., Dominguez, C., Munoz-Sanjuan, I., Bard, J., Liu, L., Verhaeghe, J., & Staelens, S.
- Affiliations
- University of Antwerp (BE)
- CHDI Foundation (US)
- CHDI Management/CHDI Foundation, Los Angeles, California, USA
- Corresponding author
- Bertoglio, Daniele
- Staelens, Steven
- ORCID
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 2022-05-14
- Volume
- 42
- Issue
- 10
- Pages
- 1867-1878
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- PMC
- PMC9536120
- OpenAlex
- W4280544176
- Cited by
- 29
- References
- 35
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 5 · 2023: 6 · 2022: 2
- FWCI
- 3.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Cerebral Blood Flow & Metabolism (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- [18F]SynVesT-1, SV2A, image-derived input function, arterial input function, radioligand kinetics, volume of distribution, test-retest reproducibility, synaptic density, central nervous system, mice
- MeSH terms
- Levetiracetam, Animals, Brain, Glycoproteins, Synaptic Vesicles, Reproducibility of Results, Radiopharmaceuticals, Positron-Emission Tomography, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Validation, kinetic modeling, and test-retest reproducibility of [ 18 F]SynVesT-1 for PET imaging of synaptic vesicle glycoprotein 2A in mice. https://app.cochat.ai/papers/10.1177/0271678x221101648
- The paper
- Bertoglio, D., Zajicek, F., Lombaerde, S. D., Miranda, A., Stroobants, S., Wang, Y., Dominguez, C., Munoz-Sanjuan, I., Bard, J., Liu, L., Verhaeghe, J., & Staelens, S. (2022). Validation, kinetic modeling, and test-retest reproducibility of [ 18 F]SynVesT-1 for PET imaging of synaptic vesicle glycoprotein 2A in mice. Journal of Cerebral Blood Flow & Metabolism. https://doi.org/10.1177/0271678x221101648
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.